Antibacterial activity of REP8839, a new antibiotic for topical use

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 10, 2005, Pages 4247-4252

  Critchley, Ian A ^a   Young, Casey L ^a   Stone, Kimberley C ^a   Ochsner, Urs A ^a   Guiles, Joseph ^a   Tarasow, Ted ^a   Janjic, Nebojsa ^a  

^a Replidyne Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; LEVOFLOXACIN; LINEZOLID; METHIONINE TRANSFER RNA LIGASE INHIBITOR; METICILLIN; PSEUDOMONIC ACID; REP 8839; TOPICAL ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; BACTERIUM ISOLATE; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PH; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-INFECTIVE AGENTS, LOCAL; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; GRAM-POSITIVE BACTERIA; HUMANS; METHIONINE-TRNA LIGASE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PROTEIN BINDING; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

EID: 25844443589     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.10.4247-4252.2005     Document Type: Article

References (44)

1. Allsop, A. E. 1998. New antibiotic discovery, novel screens, novel targets and impact of microbial genomics. Curr. Opin. Microbiol. 1:530-534.
2. Berger-Bachi, B. 1999. Genetic basis of methicillin resistance in Staphylococcus aureus. Cell. Mol. Life Sci. 56:764-770.
3. Brown, J. R., D. Gentry, J. A. Becker, K. Ingraham, D. J. Holmes, and M. J. Stanhope. 2003. Horizontal transfer of drug-resistant aminoacyl-transfer-RNA synthetases of anthrax and Gram-positive pathogens. EMBO Rep. 4:692-698.
4. Centers for Disease Control and Prevention. 1997. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. JAMA 278:1145-1146.
5. Centers for Disease Control and Prevention. 1999. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. JAMA 282:1123-1125.
6. Centers for Disease Control and Prevention. 2001. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison-Mississippi, 2000. Morb. Mortal. Wkly. Rep. 50:919-922.
7. Centers for Disease Control and Prevention. 2002. Vancomycin resistant Staphylococcus aureus-Pennsylvania, 2002. JAMA 288:2116.
8. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin-United States, 2002. Morb. Mortal. Wkly. Rep. 51:565-567.
9. Centers for Disease Control and Prevention. 2004. Vancomycin-resistant Staphylococcus aureus-New York, 2004. Morb. Mortal. Wkly. Rep. 53:322-323.
10. Chambers, H. F. 1997. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 10:781-791.
11. Cookson, B. D. 1998. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J. Antimicrob. Chemother. 41:11-18.
12. Craig, W. A., and B. Suh. 1991. Protein binding and the antimicrobial effects: methods for the determination of protein binding, p. 367-402. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, Md.
13. Decousser, J. W., P. Pina, J. C. Ghnassia, J. P. Bedos, and P. Y. Allouch. 2003. First report of clinical and microbiological failure in the eradication of glycopeptide-intermediate methicillin-resistant Staphylococcus aureus carriage by mupirocin. Eur. J. Clin. Microbiol. Infect. Dis. 22:318-319.
14. Deshpande, L. M., A. M. Fix, M. A. Pfaller, and R. N. Jones. 2002. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn. Microbiol. Infect. Dis. 42:283-290.
15. Drinka, P. J., C. Gauerke, and D. Le. 2004. Antimicrobial use and methicillin-resistant Staphylococcus aureus in a large nursing home. J. Am. Med. Dir. Assoc. 5:256-258.
16. Enright, M. C. 2003. The evolution of a resistant pathogen-the case of MRSA. Curr. Opin. Pharmacol. 3:474-479.
17. Gentry, D. R., K. A. Ingraham, M. J. Stanhope, S. Rittenhouse, R. L. Jarvest, P. J. O'Hanlon, J. R. Brown, and D. J. Holmes. 2003. Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes. Antimicrob. Agents Chemother. 47:1784-1789.
18. Guiles, J., T. Tarasow, J. Qui, I. A. Critchley, K. Stone, C. Young, U. A. Ochsner, N. Janjic, and R. L. Jarvest. 2004. Novel thiophene-containing inhibitors of bacterial methionyl tRNA synthetase: improved activity resulting from fluorovinylthiophene replacement of arylbromides, abstr. F-727, p. 204-205. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
19. Henkel, T., and J. Finlay. 1999. Emergence of resistance during mupirocin treatment: is it a problem in clinical practice? J. Chemother. 11:331-337.
20. Herold, B. C., L. C. Immergluck, M. C. Maranan, D. S. Lauderdale, R. E. Gaskin, S. Boyle-Vavra, C. D. Leitch, and R. S. Daum. 1998. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279:593-598.
21. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
22. Hoban, D. J., D. J. Biedenbach, A. H. Mutnick, and R. N. Jones. 2003. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn. Microbiol. Infect. Dis. 45: 279-285.
23. Janssen, D. A., L. T. Zarins, D. R. Schaberg, S. F. Bradley, M. S. Terpenning, and C. A. Kauffman. 1993. Detection and characterization of mupirocin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37: 2003-2006.
24. Jarvest, R. L., S. A. Armstrong, J. M. Berge, P. Brown, J. S. Elder, M. J. Brown, R. C. Copley, A. K. Forrest, D. W. Hamprecht, P. J. O'Hanlon, D. J. Mitchell, S. Rittenhouse, and D. R. Witty. 2004. Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues. Bioorg. Med. Chem. Lett. 14:3937-3941.
25. Jarvest, R. L., J. M. Berge, V. Berry, H. F. Boyd, M. J. Brown, J. S. Elder, A. K. Forrest, A. P. Fosberry, D. R. Gentry, M. J. Hibbs, D. D. Jaworski, P. J. O'Hanlon, A. J. Pope, S. Rittenhouse, R. J. Sheppard, C. Slater-Radosti, and A. Worby. 2002. Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. J. Med. Chem. 45:1959-1962.
26. Jarvest, R. L., J. M. Berge, M. J. Brown, P. Brown, J. S. Elder, A. K. Forrest, C. S. Houge-Frydrych, P. J. O'Hanlon, D. J. McNair, S. Rittenhouse, and R. J. Sheppard. 2003. Optimisation of aryl substitution leading to potent methionyl tRNA synthetase inhibitors with excellent gram-positive antibacterial activity. Bioorg. Med. Chem. Lett. 13:665-668.
27. Jarvest, R. L., J. M. Berge, P. Brown, C. S. Houge-Frydrych, P. J. O'Hanlon, D. J. McNair, A. J. Pope, and S. Rittenhouse. 2003. Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-positive antibacterial activity. Bioorg. Med. Chem. Lett. 13:1265-1268.
28. Kresken, M., D. Hafner, F. J. Schmitz, and T. A. Wichelhaus. 2004. Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int. J. Antimicrob. Agents. 23:577-581.
29. Lamb, Y. J. 1991. Overview of the role of mupirocin. J. Hosp. Infect. 19(Suppl. B):27-30.
30. Luzar, M. A., G. A. Coles, B. Faller, A. Slingeneyer, G. D. Dah, C. Briat, C. Wone, Y. Knefati, M. Kessler, and F. Peluso. 1990. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N. Engl. J. Med. 322:505-509.
31. National Committee for Clinical Laboratory Standards. 2000. Methods for determining bactericidal activity of antimicrobial agents: approved guideline M26-A. NCCLS, Wayne, Pa.
32. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. NCCLS, Wayne, Pa.
33. Niemeyer, D. M., M. J. Pucci, J. A. Thanassi, V. K. Sharma, and G. L. Archer. 1996. Role of mecA transcriptional regulation in the phenotypic expression of methicillin resistance in Staphylococcus aureus. J. Bacteriol. 178:5464-5471.
34. Ochsner, U. A., C. L. Young, K. C. Stone, F. B. Dean, N. Janjic, and I. A. Critchley. 2005. Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase. Antimicrob. Agents Chemother. 49:4253-4262.
35. Payne, D. J., M. N. Gwynn, D. J. Holmes, and M. Rosenberg. 2004. Genomic approaches to antibacterial discovery. Methods Mol. Biol. 266:231-259.
36. Poupard, J. A. 1995. Update on mupirocin resistance. J. Chemother. 7(Suppl. 3):71-74.
37. Ramsey, M. A., S. F. Bradley, C. A. Kauffman, and T. M. Morton. 1996. Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates. Antimicrob. Agents Chemother. 40:2820-2823.
38. Schmitz, F. J., A. C. Fluit, E. Lindenlauf, S. Scheuring, and K. Kohrer. 2000. Molecular analyses of possible mechanisms coding for low-level mupirocin resistance in clinical Staphylococcus aureus isolates. Eur. J. Clin. Microbiol. Infect. Dis. 19:649-650.
39. Schmitz, F. J., E. Lindenlauf, B. Hofmann, A. C. Fluit, J. Verhoef, H. P. Heinz, and M. E. Jones. 1998. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J. Antimicrob. Chemother. 42:489-495.
40. von Eiff, C., K. Becker, K. Machka, H. Stammer, and G. Peters. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 344:11-16.
41. Walker, E. S., J. E. Vasquez, R. Dula, H. Bullock, and F. A. Sarubbi. 2003. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect. Control Hosp. Epidemiol. 24:342-346.
42. Watanabe, H., H. Masaki, N. Asoh, K. Watanabe, K. Oishi, S. Kobayashi, A. Sato, R. Sugita, and T. Nagatake. 2001. Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 39:3775-3777.
43. Weinstein, H. J. 1959. Control of nasal staphylococcal-carrier states. N. Engl. J. Med. 260:1308-1310.
44. Yun, H. J., S. W. Lee, G. M. Yoon, S. Y. Kim, S. Choi, Y. S. Lee, E. C. Choi, and S. Kim. 2003. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J. Antimicrob. Chemother. 51:619-623.